Breaking News

Cellceutix Licenses Drug From NYC Cancer Center

Has potential to treat illnesses associated with cancer

Cellceutix Corp. has signed a Confidential Disclosure Agreement with a leading research and cancer treatment center in New York City for the licensing of a novel compound with the potential to treat illnesses associated with cancer. The compound is not a drug for tumor regression and could create a new market for Cellceutix.
 
Cellceutix is a clinical stage biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters